Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports Third Quarter 2017 Results and Highlights
Announced positive topline results from comparative exposure pharmacokinetic (PK) trial for Gimoti™ 505(b)(2) New Drug Application (NDA) submission on track for Q1 2018 filing Partnered with the Patheon division of Thermo Fisher Scientific Inc. as a commercial manufacturing partner for Gimoti
View HTML
Toggle Summary Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific
SOLANA BEACH, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of the Patheon division of Thermo Fisher Scientific, Inc., as the commercial
View HTML
Toggle Summary Evoke Pharma Schedules Conference Call and Webcast for Third Quarter 2017 Financial Results
SOLANA BEACH, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that the Company will release financial results for the third quarter ended September 30, 2017 on
View HTML
Toggle Summary Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti™
Call Scheduled for October 31st at 9am ET
View HTML
Toggle Summary Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti™
505(b)(2) NDA on track for FDA submission in Q1 2018
View HTML
Toggle Summary Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference
SOLANA BEACH, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company will participate in the Oppenheimer & Co.
View HTML
Toggle Summary Evoke Pharma Completes Dosing for Gimoti™ Comparative Exposure Pharmacokinetic Study
Data expected in Q4 2017 followed by a 505(b)(2) NDA submission in late 2017/early 2018
View HTML
Toggle Summary Evoke Pharma to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
SOLANA BEACH, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2017 Results and Highlights
Collaborated with Spaulding Clinical Research LLC and today announced the initiation of the comparative exposure pharmacokinetic (PK) study Partnered with Rho, Inc. for the preparation of the 505(b)(2) New Drug Application (NDA) for Gimoti™ NDA submission remains on track for late 2017/early
View HTML
Toggle Summary Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti™
Expected to be final clinical trial prior to 505(b)(2) NDA submission
View HTML